Jade Biosciences
JBIO
154 hedge funds and large institutions have $1.62B invested in Jade Biosciences in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 61 increasing their positions, 25 reducing their positions, and 16 closing their positions.
225% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 16
144% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 25
131% more capital invested
Capital invested by funds: $700M → $1.62B (+$919M)
46.62% more ownership
Funds ownership: 101.08% → 147.7% (+47%)
28% more funds holding
Funds holding: 120 → 154 (+34)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
59% less call options, than puts
Call options by funds: $802K | Put options by funds: $1.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$59.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$58.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$39.9M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$38.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.6M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$11.1M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$9.25M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.93M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$8.57M |
JBIO Hedge Fund Activity: Q2 2026 in Review
154 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2026, worth a combined $1.62B — up 131% from $700M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new JBIO positions and 16 closed out — a net gain of 36 holders — while 61 added to existing stakes and 25 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $59.6M. The largest seller was Great Point Partners, exiting entirely with an estimated $13.6M sold.
- 154 institutional investors held Jade Biosciences (JBIO) as of Q2 2026, up from 120 in Q1 2026.
- Funds reported $1.62B of Jade Biosciences stock for Q2 2026, up 131% quarter-over-quarter.
- 52 funds opened new Jade Biosciences positions in Q2 2026 and 16 closed out, a net change of +36 holders.
- The largest Jade Biosciences buyer in Q2 2026 was Paradigm Biocapital Advisors, an estimated $59.6M added.
- The largest Jade Biosciences seller in Q2 2026 was Great Point Partners, an estimated $13.6M sold.
Based on aggregated 13F filings for Q2 2026.